CSL112 ENHANCES THE ABILITY OF SERUM TO EFFLUX CHOLESTEROL IN PATIENTS WITH MODERATE RENAL IMPAIRMENT
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)33443-5
Abstract: Background: CSL112 is a novel formulation of plasma-derived apolipoprotein A-I (apoA-I) that is in development for cardiovascular (CV) event reduction following acute coronary syndrome (ACS) by enhancement of cholesterol efflux capacity (CEC). Completed clinical trials… read more here.
Keywords: csl112; csl112 enhances; ability serum; cholesterol ... See more keywords